Sjögren's Disease and Cancer: Key Predictors From the Spanish Multicenter SjögrenSER-TRANS Cohort.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rusinovich-Lovgach Olga, Plaza Zulema, Castro Mónica Fernández, Sánchez-Piedra Carlos, Rosas José, Martínez-Taboada Victor, Olivé Alejandro, Menor Almagro Raul, Rodrígez-Lozano Beatriz, Garcia-Aparicio Angel, Lopez Longo Francisco Javier, Manrique-Arija Sara, Garcia-Vadillo Jesús Alberto, Gil Barato Susana, Lopez-Gonzalez Ruth, Narvaez García Javier, Galisteo Lencastre Carlos, Gonzalez-Martin Jorge, Alonso Fernando, Andreu Jose Luis, SJÖGRENSER Group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER)
Аннотация
METHODS: A retrospective, cross-sectional study was conducted using data from the SjögrenSER-TRANS registry, a national cohort of 437 SjD patients from 33 Spanish hospitals who fulfilled the 2002 AECG classification criteria. Clinical, serological, and treatment-related variables were systematically collected. Descriptive statistics were used to summarize demographic and clinical characteristics. Bivariate analysis (chi-squared for categorical variables and t-tests for continuous variables) was performed to identify associations with malignancy (p < 0.05), followed by multivariate logistic regression to determine independent predictors.
RESULTS: Malignancy was identified in 30 patients (6.86%), with gynecological cancers (30%) and lymphomas (23.3%) being the most common types. Independent predictors of malignancy included older age (OR 1.042, 95% CI 1.007-1.079), glandular inflammation (OR 2.888, 95% CI 1.281-6.512), and rituximab use (OR 3.959, 95% CI 1.461-10.730).
CONCLUSION: This study underscores the role of older age, glandular inflammation, and rituximab use as key risk factors for malignancy in SjD. However, the association with rituximab should be interpreted with caution, as indication bias cannot be ruled out. These findings emphasize the need for improved risk stratification and targeted surveillance strategies to facilitate early detection and enhance malignancy management in clinical practice. Prospective studies are warranted to refine monitoring protocols and optimize patient outcomes.